<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04042155</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-ACO-2018-31</org_study_id>
    <nct_id>NCT04042155</nct_id>
  </id_info>
  <brief_title>Real-life Clinical Outcomes of Direct Oral Anticoagulants (MACACOD)</brief_title>
  <acronym>MACACOD</acronym>
  <official_title>Clinical Application Model of Direct Oral Anticoagulants (MACACOD). Comprehensive Management of ACOD From a Specialized Center in Antithrombotic Therapy and Its Area of Influence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      MACACOD is a clinical record in the usual clinical practice of direct oral anticoagulants
      (dabigatran, rivaroxaban, apixaban and edoxaban). Design: single-center, observational,
      prospective, uncontrolled study of anticoagulated patients with any direct oral anticoagulant
      (DOAC) with atrial fibrillation or venous thromboembolism to determine the incidence of
      serious complications (thromboembolic or hemorrhagic) in real life
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Population: Patients over 18 years of age, with recurrent atrial fibrillation or venous
      thromboembolism, already anticoagulated with any DOAC or patients who initiate therapy with
      DOAC and who give their consent. Upon entering the study, demographic data, previous
      anticoagulant treatments, previous serious complications, comorbidities and baseline
      analytical results are recorded. The risk scores CHA2DS2-Vasc, HAS-BLED and Charlson
      comorbidity index (CCI) are calculated. The type of health education received in relation to
      anticoagulant therapy is also recorded. During the follow-up, complications and clinical
      changes and the analytical results of coagulation, renal and hepatic function will be
      recorded. The risk scores will be updated at each visit. In case of serious complications,
      the associated costs will be estimated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 29, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Thromboembolic events</measure>
    <time_frame>3 years</time_frame>
    <description>Any documented embolic stroke, peripheral arterial embolism or venous thromboembolism</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major haemorrhagic events</measure>
    <time_frame>3 years</time_frame>
    <description>Any documented bleeding event grade 3 or 5 in the Bleeding Assessment Research Consortium (BARC) scale Full scale name: Bleeding Assessment Research Consortium Scale ranges: 0-5 Where 0 is the better result and 5 is the worst</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other thrombotic events</measure>
    <time_frame>3 years</time_frame>
    <description>Myocardial infarction, transient ischemic attack, superficial thrombophlebitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically (non major) relevant bleeding</measure>
    <time_frame>3 years</time_frame>
    <description>Any documented bleeding event grade 2 in the Bleeding Assessment Research Consortium (BARC) scale Full scale name: Bleeding Assessment Research Consortium Scale ranges: 0-5 Where 0 is the better result and 5 is the worst</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>3 years</time_frame>
    <description>Death from any cause</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1600</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Recurrent Venous Thromboembolism</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dabigatran, rivaroxaban, apixaban or edoxaban</intervention_name>
    <description>Record of all serious complications associated with any of the drugs and the clinical changes that occurred during prospective follow-up.</description>
    <other_name>Pradaxa, Xarelto, Eliquis or Lixiana</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma samples remaining from the routine blood tests.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients under treatment with DOAC controlled at the Hospital de Sant Pau in Barcelona and
        in their area of influence (Primary Care Centers). These patients must be older than 18
        years, with atrial fibrillation or recurrent venous thrombosis.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        · Patients older than 18 years.

          -  With atrial fibrillation or recurrent venous thrombosis.

          -  In chronic treatment with any DOAC type drug.

          -  Patients who sign the informed consent

        Exclusion Criteria:

          -  Patients who do not guarantee collaboration.

          -  Patients with advanced cognitive impairment and not supervised.

          -  Patients with alcoholism.

          -  Patients with psychiatric disorder and not supervised
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan C Souto, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de la Santa Creu i Sant Pau. Barcelona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juan C Souto, MD, PhD</last_name>
    <phone>34-654633993</phone>
    <email>jsouto@santpau.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <state>Catalonia</state>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan C Souto, MD, PhD</last_name>
      <phone>34-654633993</phone>
      <email>jsouto@santpau.cat</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 30, 2019</study_first_submitted>
  <study_first_submitted_qc>July 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2019</study_first_posted>
  <last_update_submitted>August 19, 2019</last_update_submitted>
  <last_update_submitted_qc>August 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dabigatran</keyword>
  <keyword>rivaroxaban</keyword>
  <keyword>apixaban</keyword>
  <keyword>edoxaban</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Apixaban</mesh_term>
    <mesh_term>Edoxaban</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

